Patient Leaflet Updated 21-Nov-2024 | Roche Products Limited
Phesgo 600 mg/600 mg, 1200 mg/600 mg solution for injection
Phesgo 600 mg/600 mg solution for injection
Phesgo 1200 mg/600 mg solution for injection
pertuzumab/trastuzumab
▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.
1. What Phesgo is and what it is used for
2. What you need to know before you are given Phesgo
3. How you are given Phesgo
4. Possible side effects
5. How to store Phesgo
6. Contents of the pack and other information
Phesgo is a cancer medicine that contains two active substances: pertuzumab and trastuzumab.
Phesgo is available in two different strengths. See section 6 for more information.
Phesgo is used to treat adult patients with breast cancer that is of the “HER2-positive” type – your doctor will test you for this. It can be used when:
As part of your treatment with Phesgo you will also receive other medicines called chemotherapy. Information about these medicines is described in separate package leaflets. Ask your doctor, pharmacist or nurse to give you information about these other medicines.
If you are not sure, talk to your doctor, pharmacist or nurse before you are given Phesgo
Heart problems
Treatment with Phesgo may affect the heart. Talk to your doctor, pharmacist or nurse before you are given Phesgo if:
If any of the above applies to you (or you are not sure), talk to your doctor or nurse before you are given Phesgo. See section 4 “Serious side effects” for more details about signs of heart problems to look out for.
Injection reactions
A reaction to the injection can happen. These are allergic reactions and can be severe.
If you get any serious reaction, your doctor may stop treatment with Phesgo. See section 4 ‘‘Serious side effects’’ for more details about injection related reactions to look out for during the injection and thereafter.
Your doctor or nurse will check for side effects during your injection and for:
If you get any serious reaction, your doctor may stop treatment with Phesgo.
Low levels of white blood cells and fever (Febrile neutropenia)
When Phesgo is given with chemotherapy medicines, the number of white blood cells may drop and fever may develop. If you have inflammation of the digestive tract (e.g. sore mouth or diarrhoea) you may be more likely to develop this side effect. If the fever persists for several days, this may be a sign of worsening of your condition and you should contact your physician.
Diarrhoea
Treatment with Phesgo may cause severe diarrhoea. Patients over 65 years of age have a higher risk of diarrhoea compared with patients younger than 65 years of age. If you get severe diarrhoea during your cancer treatment, your doctor may give you medicines to control diarrhoea. Your doctor may also stop your treatment with Phesgo until the diarrhoea is under control.
Phesgo should not be given to patients under the age of 18 years because there is no information on how it works in this age group.
Patients over 65 years of age are more likely to get side effects such as reduced appetite, decrease in the number of red blood cells, weight loss, tiredness, loss or altered taste, weakness, numbness, tingling or prickling sensations mainly affecting the feet and legs and diarrhoea, compared to patients younger than 65 years of age.
Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines.
Before starting treatment, you must tell your doctor, pharmacist or nurse if you are pregnant or breast-feeding, or if you think you may be pregnant or are planning to have a baby. They will discuss with you the benefits and risks for you and your baby of taking Phesgo while you are pregnant.
Phesgo may affect your ability to drive or operate machines. If during treatment you experience symptoms, such as feeling dizzy, chills, fever or any injection or allergic reactions as described in section 4, you should not drive or use machines until these symptoms disappear.
Phesgo contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially sodium-free.
Phesgo will be given to you by a doctor or nurse in a hospital or clinic as an injection under your skin (subcutaneous injection).
Subsequent injections (maintenance doses), which will be given if the first injection have not caused severe side effects:
For further information on loading and maintenance dose see section 6.
For further information on dosing of chemotherapy (which can cause side effects as well), please read the package leaflet for these medicines. If you have questions about them, please ask your doctor, pharmacist or nurse.
If you miss your appointment to have Phesgo make another appointment as soon as possible. Depending on how much time passed between the two visits, your doctor will decide which strength of Phesgo to give you.
Do not stop your treatment with this medicine without talking to your doctor first. It is important that you are given the full course of injections at the right time every three weeks. This helps your medicine work as well as it can.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Tell a doctor or nurse straight away, if you notice any of the following side effects:
Tell a doctor or nurse straight away, if you notice any of the side effects above.
Very common (may affect more than 1 in 10 people):
Common (may affect up to 1 in 10 people):
Uncommon (may affect up to 1 in 100 people):
If you get any of the side effects above, talk to your doctor, nurse or pharmacist.
If you get any of the above after treatment with Phesgo has been stopped, you should get in touch with your doctor immediately and say that you have previously been treated with Phesgo.
Some of the side effects which you get may be due to your breast cancer. If you are given Phesgo with chemotherapy at the same time, some side effects may also be due to these other medicines.
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects you can help provide more information on the safety of this medicine.
United Kingdom
or search for MHRA Yellow Card in the Google Play or Apple App Store
Phesgo will be stored by the health professionals at the hospital or clinic. The storage details are as follows:
The active substances are pertuzumab and trastuzumab.
The other ingredients are vorhyaluronidase alfa, L-histidine, L-histidine hydrochloride monohydrate, α,α-trehalose dihydrate, sucrose, L-methionine, polysorbate 20 and water for injections (see section 2 “Phesgo contains sodium”).
Phesgo is a solution for injection. It is a clear to opalescent solution, colourless to slightly brown supplied in a glass vial. Each pack contains one vial with either 10 mL or 15 mL solution.
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
This leaflet was last revised in January 2022
gb-pil-phesgo-clean-220126-600mg-1200mg-inj
Hexagon Place, 6 Falcon Way, Shire Park, Welwyn Garden City, Hertfordshire, AL7 1TW
+44 (0)1707 338 297
+44 (0)800 731 5711
+44 (0)1707 384555
+44 (0)1707 366 000
+44 (0)800 328 1629
http://www.roche.co.uk